Report: Cancer Drug Discoveries: Renal Cancer TOC

RENAL CELL CARCINOMA
- EXECUTIVE SUMMARY
THE FACTS
- What is RCC and why are we interested in it?
  - Figure 6.1: Structure of the Kidney
  - PATIENT STATISTICS
    - Incidence, diagnosis rates and treatment; now and in the future
      - Figure 6.2: World age-standardised incidence rates for kidney cancer, selected countries, 2002 estimates
  - PATIENT MODEL
    - The number of patients with RCC will have a CAGR 2005A-2012E of 2.67%.
      - Table 6.1: Summary of Patient Population Forecasts
  - DRUG GROWTH DRIVERS
  - DRUG GROWTH RISKS/DAMPENERS
THE MARKET
- GLOBAL CANCER MARKET
  - Figure 6.3: Global Cancer Drug Sales (including Supportive Care) in 2006 (US$47 billion)
  - Figure 6.4: Global Cancer Sales 2004A-2012E
- THE RCC MARKET
- GLOBAL SALES SPLIT
  - Figure 6.5: Global sales split (2006)
- US market
  - Figure 6.6: RCC US Drugs Sales Split (2006A)
- European market
  - Figure 6.7: RCC European Drugs Sales Split (2006A)
- Japanese market
- The major players
- Players and Products in 2006
- Players and products in 2012
  - Figure 6.9: Global Market share of RCC players by sales (Dec 2012E)
- CURRENT TREATMENTS
  - Leading Brands
    - Table 6.2: Comparison of Leading RCC Agents
  - Current Products' Patent Exposure
    - Table 6.3: Patent Exposure of Leading Brands
- ANALYSIS OF LEADING BRANDS
  - Immunomodulating agents
    - Immunomodulating agents
      - Interferon (IFN) alpha
      - Intron A/PEG-Intron (Schering-Plough)
      - Roferon-A/Pegasys (Roche)
        
        Novelty/rationale for mechanism of action
        Proof of concept/clinical data
        Management/clinical expertise
        Competition within the marketplace/gaining share of voice
        Risks associated with developing a drug within a therapeutic class
        Filings and approval
        Sales forecasts and assumptions
        Table 6.4: Sales forecasts for interferon products
        Competitor Ratio Analysis
  - Proleukin (Novartis/Chiron)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Nexavar (Bayer/Onyx Pharmaceuticals)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Sutent (Pfizer)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005A- 2012E
- Table 6.5: Sales Forecasts of Current Leading RCC Drugs (US$ millions)
- Model assumptions
- NEW DRUGS IN R&D
  - Table 6.6: Drugs in Development to Treat RCC
ANALYSIS OF PHASE III DRUGS
- Table 6.7: New Drugs in Phase III Development to Treat RCC
  - Avastin (Roche/Genentech/Chugai)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Everolimus (Novartis)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Pazopanib (GlaxoSmithKline)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Rencarex (Wilex)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Torisel (Wyeth)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - TroVax (Oxford BioMedica/sanofi-aventis)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Tykerb (GlaxoSmithKline)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
GLOBAL SALES FORECASTS OF PHASE III RCC DRUGS 2006E- 2012E
- Table 6.8: Sales Forecasts of Phase III Developmental RCC Drugs (US$ million)
- Model assumptions
ANALYSIS OF PHASE II DRUGS
- Table 6.9: New Drugs in Early Clinical Development to Treat RCC
- Immunomodulators
- Angiogenic inhibitors
- Novel agents
- Immunomodulators
  - rIL-21 (ZymoGenetics/Novo Nordisk)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Revlimid (Celgene)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Talactoferrin (Agennix)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
- Angiogenesis inhibitors
  - ABT-510 (Abbott)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
- Novel agents
  - AS1411 (Antisoma)
    - Novelty/rationale for mechanism of action
    - Proof of concept/clinical data
    - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Competitor Ratio Analysis
  - Other Interesting Phase II Drugs
    - ABT-751 (Abbott)
    - Recentin (AstraZeneca)
    - GTI-2040 (Lorus Therapeutics)
    - Ipilimumab (Medarex/Bristol-Myers Squibb)
    - Ixabepilone (Bristol-Myers Squibb)
    - Vatalinib (Novartis/Bayer Schering Pharma)
    - Volociximab (PDL BioPharma/Biogen Idec)
    - XL880 (Exelixis)
GLOBAL SALES FORECASTS OF PHASE II RCC DRUGS 2006A - 2012E
- Table 6.10: Sales Forecasts of Phase II Developmental RCC Drugs (US$ million)
  - Model assumptions
COMPETITOR RATIO ANALYSIS - PRODUCTS
- Table 6.11: Rating Score for Clinical Rating
- Figure 6.11: CR Analysis of RCC Agents Approved by 2012 - Based on Drug Class
- COMPETITOR RATIO ANALYSIS - COMPANIES
  - Figure 6.12: CR Analysis of RCC Agents Approved by 2012 - Based on Company
- WINNERS & LOSERS
  - Table 6.12: Summary of Key Companies and Drugs in the RCC Market by 2012
  - Winners (alphabetical)
  - Losers
DISCONTINUATION OF DRUGS
- Table 6.13: Drugs Discontinued (or ' on hold' ) from Clinical Development in RCC
APPENDIX 1
- Figure 6.13: RCC Tumour Staging Systems
- Tumor, Node, Metastasis (TNM) Staging of Renal Cell Carcinoma
APPENDIX 2
- Phase Transition Probability
  - Table 6.14: Probability of Launch
Appendix 3
- Patient Model
  - Table 6.15: Summary of US RCC Patient Population Forecasts
  - Table 6.16: Summary of Europe (Top 5) RCC Patient Population Forecasts
  - Table 6.17: Summary of Japan RCC Patient Population Forecasts
Appendix 4
- Table 18: Global RCC Drugs Sales 2005A-2012E
APPENDIX 5
- Competitor Ratio Analysis Criteria
- Table 6.19: Key RCC Drugs on the Market by 2012
GLOSSARY
REFERENCES
ACRONYMS

Cancer Drug Discoveries: Renal Cancer

Table of Contents